chrisvoncsefalvay/vaers-outcomes huggingface dataset:
pain at the right side of his lungs and he doesn't know if it was piling up with fluids and this had been bothering him; pain at the right side of his lungs and he doesn't know if it was piling up with fluids and this had been bothering him; when he stretches, he feels like " his right lung is scratching up against something and that it was temperature sensitive; when he stretches, he feels like " his right lung is scratching up against something and that it was temperature sensitive; This is a spontaneous report from a contactable consumer (patient). An 80-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), via an unspecified route of administration on 03Jul2021 (Batch/Lot number was not reported) as dose 1, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient previously received pneumococcal shot (over 65 flu type) on unspecified date in 2021 and experienced he had a little pain, then after 3-4 weeks took Pfizer COVID-19 vaccine. The patient had the first dose of the Pfizer BioNTech COVID-19 vaccine last 03Jul2021, stated that he was given a "Pulmonary Flu Shot" a month and a half before. He mentioned that on Jul2021 he had experienced pain at the right side of his lungs and he doesn't know if it was piling up with fluids and this had been bothering him. He also mentioned that when he stretches, he feels like "his right lung is scratching up against something and that it was temperature sensitive". It was said that if it's hot, he could take his shirt off and then the pain would seize. Patient wanted to know if these had been reported as side effect with the Pfizer BioNTech COVID-19 vaccine. Patient called about symptomatic stuff to ask what happens if you have certain actions. He said "you know a little before the 19 started", he was breathing normally then something took his right lung, he doesn't know what or how. He said for 6-8 months at night when he turned over it would wake him up. He said one of the things he did before anything else was he took the pneumococcal thing, the over 65 flu type, he took that, then after 3-4 weeks from there, he took the Pfizer flu shot and he was wondering if he should wait a bit longer than three months or three weeks for the second. He said after the pneumococcal shot he had a little pain, he thought before that he must have been exposed to that flu, he didn't know if he has it now, it has subsided. He said he was supposed to go get the second shot, he wanted to know if he was supposed to have any other interference with it. Patient said on the back page it said it was a low situation. Patient clarified that he had his Pfizer first shot, "GT19 or the 19 ". Patient clarified he meant the Pfizer COVID-19 vaccine. The outcome of the events was unknown.  Information about the lot/batch number has been requested.
One day after: for around half a day from early afternoon to early evening, my upper arm and shoulder was painful. It was a tingling  pain and the pain was fairly intense (more painful than I have experienced with other vaccines). 1.5 weeks after: My period came 2.5 weeks early and it was heavier than normal. This is especially surprising given that I am on birth control pills to regulate my period due to PCOS and never experience early periods while on this medication.
severe fever, malaise, weakness, arm pain, dizziness lasting 3 days, still recovering. limited responsiveness to motrin/tylenol/aspirin
Patient received Hep A #1. She felt fine. She bent forward to tie her shoe and describes pain from (R) deltoid site of vaccination that spread to (R) shoulder, ant chest wall, (R) jaw. Lasted 2 min. totally resolved.
Left arm where pt. received Tdap on 8/2/11 is red, swollen, warm to touch with hard middle. Area of redness 7cm W x 5cm high on (L) deltoid. Pt has applied ice & has taken TYLENOL.
pt recv vax 4JAN96 & 21AUG97 pt devel a zoster type rash which was not eval by MD first hand;
Pulse rate is continuously in 100s, sometimes shoots to 120-130. Also Pulse rate increases sharply if I stand up
Angioedema; eye swelling; lip swelling.; This case was reported by a physician via sales rep and described the occurrence of angioedema in a 53-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent 2021-2022 season) for prophylaxis and ibuprofen for product used for unknown indication.   In September 2021, the patient received the 1st dose of Shingrix and Influenza vaccine Quadrivalent 2021-2022 season. On an unknown date, the patient started ibuprofen at an unknown dose and frequency. On an unknown date, less than a week after receiving Shingrix and Influenza vaccine Quadrivalent 2021-2022 season, the patient experienced angioedema (serious criteria GSK medically significant), eye swelling and lip swelling. The patient was treated with benadryl (nos) (Benadryl). Ibuprofen was discontinued. On an unknown date, the outcome of the angioedema and lip swelling were unknown and the outcome of the eye swelling was recovered/resolved.   It was unknown if the reporter considered the angioedema, eye swelling and lip swelling to be related to Shingrix and Influenza vaccine Quadrivalent 2021-2022 season.  Additional details were provided as follows:  The age at vaccination was unknown. The patient was taking Ibuprofen. In September 2021, the patient with no known comorbidities received dose 1 of Shingrix vaccine and a flu vaccine on the same visit.  On the next day, the patient reported to the reporting physician that she had eye swelling.  The reporter told her to take Benadryl, go to urgent care and reporter referred her to an allergist.  Eye swelling resolved the next day with the Benadryl so she pursued no further follow up at that time.  A couple of months later, she experienced a second episode of swelling so went directly to the allergist.  The patient was seen by allergist and reported that initial episode involved both eye and lip swelling. Allergist conducted food testing which was negative. Allergist suspected the reaction was caused by Ibuprofen and told patient to take no further Ibuprofen. Allergist ordered Meloxicam challenge (had not yet been done) and told the patient that he did not think the allergic reaction was due to the Shingrix vaccine. The patient wanted to receive dose 2 of Shingrix but reporter was uncomfortable administering Shingrix dose 2 to her since there was no surety that the vaccine did not contribute to her angioedema.  Nor did reporter thought she should receive dose 2 in a pharmacy in case she had a severe reaction that they were unable to handle. The reporter did not agree to follow up. He previously reported to VAERS. The reporter considered the angioedema, eye swelling and lip swelling to be possibly related to Ibuprofen.
A report has been received from a Health Professional concerning a 1 year old, Male subject, who had been receiving Nasal FLUMIST QUARIVALENT(Intranasal). FLUMIST QUADRIVALENT (Intranasal) started on 17-Jan-2014. It was reported that FLUMIST QUADRIVALENT was administered to 12 months old which started on 17-Jan-2014. The outcome of the event of administered FLUMIST QUADRIVALENT to a 1 yo is unknown. The report was considered to be non-serious.
Patient was double vaccinated for influenza in the same season of 2022. Patients father was made aware f the incident. Patient was monitored and stable prior to discharge from the practice.
Patient arrives today for rash. Mom states rash appeared 2 days ago and has gotten worse. Dr diagnosed rash as measles type rash due to vaccine without complications.
Fever, chills, minimal nausea, increased shortness of breath, increased body aches and pain, increased fatigue, injection site pain and slight swelling (including numbness in back of arm).
5 month old with spots on body, started 3 days ago along with diarrhea;  cough x 4 days temp 98 R 148-38 Stuffy nose, yellowish nasal drainage.  A few red spots on soles of feet + palms of hands.  History of cough/runny nose on 3-5-09.
Metallic smell/taste; Metallic smell; Elevated heartrate; Flushed; Tiredness; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199), via an unspecified route of administration at left arm on 16Mar2021 at 13:15 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history of the patient included hypertension, ADHD , anxiety/depression and also had allergy to contrast dye. Concomitant medications included losartan (MANUFACTURER UNKNOWN), hydrochlorothiazide (MANUFACTURER UNKNOWN) and escitalopram (MANUFACTURER UNKNOWN); all for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient didn't receive any other vaccine within 4 weeks prior to COVID-19 vaccine. On 16Mar2021 at 13:30, the patient experienced metallic smell, metallic taste, elevated heart rate, flushed and tiredness. No therapeutic measures were taken for the events. The clinical outcome of metallic smell, metallic taste, elevated heart rate, flushed and tiredness was resolved on an unknown date at the time of this report. No follow-up attempts are needed. No further information is expected.
Abrupt return of Parkinson's symptoms: tremor, rigidity, unable to walk, no balance, REM sleep disturbance
Flu like symptoms; nausea; nuchal headache; Tiredness; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms), NAUSEA (nausea), HEADACHE (nuchal headache) and FATIGUE (Tiredness) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 020B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 09-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms), NAUSEA (nausea), HEADACHE (nuchal headache) and FATIGUE (Tiredness). At the time of the report, INFLUENZA LIKE ILLNESS (Flu like symptoms), NAUSEA (nausea), HEADACHE (nuchal headache) and FATIGUE (Tiredness) outcome was unknown.            The concomitant medications information was not reported. Treatment information was not provided.    This case was linked to MOD-2021-051274 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 12-Jul-2021: Follow up was received. No new information was provided.
generalized pain for 2 hours that improved over the course of 2 hours. bilateral knee pain persists
2 weeks of bad cough; flu; Initial information received on 29-Dec-2022 regarding an unsolicited valid Social Media non-serious case received from a consumer/non-hcp (non-health care professional).  This case involves an unknown age and unknown gender patient who had 2 weeks of bad cough and flu after receiving  INFLUENZA VACCINE.  The patient's past medical history, concomitants, medical treatment(s), vaccination(s) and family history were not provided.  On an unknown date, the patient received unknown  dose of suspect INFLUENZA VACCINE ( with unknown strength, form, route, frequency, batch number and expiry date ) at  unknown administration site for prophylactic vaccination.  On an unknown date the patient had non-serious events 2 weeks of bad cough (cough) and flu (influenza) (unknown latency) .  It is unknown if the patient had any medical history, concomitant disease or risk factor.  No lab data included  Action taken : not applicable.  It was not reported if the patient received a corrective treatment for the events (2 weeks of bad cough, flu).  Outcome : recovering/ resolving for both events.
Narrative:  84 y/o male presented to ER on 1/22/22 with progressive dyspnea with intermittent chest pain for a week and a half. Treated with dexamethasone only as other COVID treatments were contraindicated. Patient died on 1/25/22. PMH includes DM, hyperlipidemia, ischemic heart disease, s/p coronary bypass, COPD, HTN, obesity, CKD and CHF.
This case was reported by a consumer via call center representative and described the occurrence of injection site rash in a 69-year-old female patient who received SHINGRIX for prophylaxis. On 20th August 2018, the patient received SHINGRIX. On 21st August 2018, 1 days after receiving SHINGRIX, the patient experienced injection site rash. On an unknown date, the outcome of the injection site rash was unchanged. It was unknown if the reporter considered the injection site rash to be related to SHINGRIX. Additional details were provided as follows: The patient had a rash at the injection site after receiving the SHINGRIX vaccine in the left arm. The patient stated that, the rash was getting worse.
CONFIRMED IMMUNOLOGICAL VACCINE FAILURE; This spontaneous report received from a health care professional concerned a 67 year old male. The patient's weight, height, and medical history were not reported. The patient received COVID-19 VACCINE AD26.COV2.S (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 07-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  The patient did not show antibodies when he got tested using the serology IgG test on 31-MAR-2021. Laboratory data included: Serology Immunoglobulin G (NR: not provided) did not found Antibodies. Also he did not show antibodies when he got tested using SARS-COV2-Antibody IgG, spike ,semi quantitative on 20APR-2021 and 27-APR-2021 as well (confirmed immunological vaccine failure.) . Laboratory data included: COVID-19 antibody test (NR: not provided) did not found Antibodies. It was not known where he got vaccinated or his personal information.  The action taken COVID-19 VACCINE AD26.COV2.S was not applicable. The outcome of confirmed immunological vaccine failure was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: 20210509824- COVID-19 VACCINE AD26.COV2.S-Confirmed Immunological Vaccine Failure. This event(s) is considered not related. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event(s) than the drug. Specifically: SPECIAL SITUATIONS.
POTS; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a 16-year-old female patient. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On an unknown date, the patient was vaccinated with Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) for prophylaxis. On an unspecified date in 2010 (reported date of injury), the patient experienced Postural orthostatic tachycardia syndrome (POTS). At the time of the report, the patient's outcome was unknown. According to reporter, the event was related to the suspect therapy.
Initial report received from a health care professional on 26 Oct 2010: On 08 Oct 2010, this patient received a intramuscular dose of only the MenCYW-135 liquid conjugate component of MENVEO (batch number: 100001(box) 090901), (dose unknown). The patient did not receive MenA lyophilized conjugate component of MENVEO. No adverse effect occurred. The outcome of the event was not reported.
Vaccine given on 7/13/2005. MD evaluated on 7/13/2005. Redness and swelling left deltoid reduced on 7/17/2005. DTaP given in left deltoid.
hives noted developing on anterior chest wall, extending down chest and to bilateral arms; Moderate facial edema extending into ears, moderate edema to oropharynx; tachycardic; This spontaneous case was reported by an other health care professional and describes the occurrence of URTICARIA (hives noted developing on anterior chest wall, extending down chest and to bilateral arms), SWELLING FACE (Moderate facial edema extending into ears, moderate edema to oropharynx) and HEART RATE INCREASED (tachycardic) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (no historical condition was reported).    On 18-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jan-2021, the patient experienced URTICARIA (hives noted developing on anterior chest wall, extending down chest and to bilateral arms), SWELLING FACE (Moderate facial edema extending into ears, moderate edema to oropharynx) and HEART RATE INCREASED (tachycardic). At the time of the report, URTICARIA (hives noted developing on anterior chest wall, extending down chest and to bilateral arms), SWELLING FACE (Moderate facial edema extending into ears, moderate edema to oropharynx) and HEART RATE INCREASED (tachycardic) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Pt received pfizer vaccine on 03/18/21 and 04/08/21. While inpatient, pt tested positive for COVID. CXR showed developing COVID pneumonia.
Patient reports dizziness 3 hours after getting vaccination and nausea. Dizziness has since resolved
Patient's daughter states that about 3 hours after the patient received the vaccine the patients arm was swelling and producing red welts. They called the primary physician and the office recommended BENADRYL. Symptoms resolved within 2 days no office visit required.
did not get her second dose until 8th June 2023; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 78-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on 3rd September 2018).   On 08-JUN-2023, the patient received the 2nd dose of Shingrix. On 08-JUN-2023, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: did not get her second dose until 8th June 2023). The outcome of the drug dose administration interval too long was unknown.   Additional Information: GSK Receipt Date: 06-JUL-2023 The reporter did not consent to follow-up. The patient received 2nd dose of Shingrix later than the recommended schedule, which led to lengthening of vaccination schedule.
Pt recvd a series of 3 Engerix-B on 19APR90, 14JUN90 & 14NOV90 & was a poss non-responder;
Right deltoid with erythema, edema and tenderness; Right axillary lymphnode enlargement and tenderness; Fever Tmax 102.7, generalized body aches, chills and rigors all within 24 hours of 2nd dose of vaccine. Slightly relieved with Tylenol 650 mg & Ibuprofen 200 mg po & warm compresses to right axilla. 48 hours after vaccine, fever Tmax 101.3, lower extremity body aches, chills, right deltoid and right axillary with edema and tenderness. Slightly relieved with Tylenol 650mg po, 72 hours after vaccine, upper back aching, slight dizziness with brain fog, and extreme fatigue. Pushing fluids and stretching.
Face swelled, tongue swollen, throat tight hard to swallow, sore throat with pain radiating out and up into ears.
4/25 Pt presented to urgent care with complaint of HA and earache. Her pulse ox was in the 80's and she was sent to the ED for further evaluation and admission.  D/C summary from 4/26 : Patient is a 58 y.o. female patient of, DO with history of OSA cannot tolerate CPAP, depression, rheumatoid arthritis, chronic pain syndrome, obesity, diabetes type 2, CAD, hypertension, hyperlipidemia, TIA who presents with shortness of breath. Patient was placed on 4 L NC but quickly weaned off. She tested positive for covid on 4/25. She was started on dexamethasone and covid cocktail for 10 days. Her CTPA and venous duplexes were negative for blood clots. There was bronchitis on CTPA so pt was placed on albuterol, mucinex and advised to use IS. Her Cr was elevated to 1.52 and improved to 1.25 this morning. Her hydrochlorothiazide was held. Her AST was 186, ALT 245 previously normal. Her atorvastatin and metformin were held. She was tolerating po and her VS were stable so she was discharged home. She was advised to have repeat labs with her PCP in 1 week and if at that time her Cr, AST, ALT improved, then her hydrochlorothiazide, atorvastatin, metformin could be resumed at her PCP's discretion. She was at home for one day and presented to another ED with CP and SOB. Admitted 4/27-5/1 D/C Summary :Clinical Summary Patient is a 58 y.o. female with a history of positive covid test 4/25/21, CKD, CAD s/p PCI, depression OSA rheumatoid arthritis morbid obesity, HTN and DM2 who just discharged from hospital 4/26/21 after diagnosis of COVID and starting on dexamethasone. She presented to hospital 4/27/2021 with chest pain and shortness of breath. CXR negative 4/27/21, CTPA negative 4/26/21, LEVD negative 4/26/21 labs stable from last admission.    1. COVID 19 Pneumonia: Suspected re-infection. Husband reported was positive mid - January. Continued dexamethasone to complete 10 days (started 4/25/2021). Remdesivir not started with LFT elevation on admit.  2. Acute hypoxic respiratory failure: with increasing O2 requirement 4/28/2021. CXR 4/28/2021 with underaeration of lungs. ABG 4/28/2021 without hypoxemia. Likely d/t COVID, resolved 3. Chest pain: Suspect in setting of COVID infection and component of costochondritis. CTPA and LEVD negative 4/26/21. Troponins stable from last admission in setting of CKD, ekg without acute findings on admit.  4. Elevated LFT: on admit AST 186, ALT 245, total bilirubin 0.2. likely d/t COVID. Improving, AST 93, ALT 163 4/30/202.1. will need outpatient repeat in 1-2 weeks with PCP 5. CKD3: Baseline creat 1.2-1.5. Cr on admit 1.52, improved 0.99 4/30/2021. Repeat chem in 1-2 weeks  6. T2DM: Per history, on Januvia at home (held on admit). A1C 8 1/29/21. Hyperglycemia on admission, improved with SSI, discussed continuing on discharge while on steroids and following up with PCP in next week